$1.57
+0.09 (+6.08%)
Open$1.52
Previous Close$1.48
Day High$1.58
Day Low$1.50
52W High$8.47
52W Low$5.34
Volume—
Avg Volume596.5K
Market Cap146.74M
P/E Ratio15.59
EPS$0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+414.6% upside
Current
$1.57
$1.57
Target
$8.08
$8.08
$6.79
$8.08 avg
$13.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 52.03M | 54.83M | 47.58M |
| Net Income | 8.35M | 10.00M | 7.87M |
| Profit Margin | 16.0% | 18.2% | 16.6% |
| EBITDA | 16.78M | 16.80M | 15.25M |
| Free Cash Flow | 8.41M | 9.93M | 9.62M |
| Rev Growth | +22.7% | -2.4% | +14.5% |
| Debt/Equity | 0.63 | 0.64 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |